Minority Views
[To accompany H.R. 4424]
[Including cost estimate of the Congressional Budget Office]
The Committee on Veterans' Affairs, to whom was referred
the bill (H.R. 4424) to direct the Secretary of Veterans
Affairs to study and report on the prevalence of
cholangiocarcinoma in veterans who served in the Vietnam
theater of operations during the Vietnam era, and for other
purposes, having considered the same, reports favorably thereon
with an amendment and recommends that the bill as amended do
pass.
CONTENTS
Page
Amendment........................................................ 2
Purpose and Summary.............................................. 2
Background and Need for Legislation.............................. 3
Hearings......................................................... 4
Subcommittee Consideration....................................... 4
Committee Consideration.......................................... 4
Committee Votes.................................................. 5
Committee Correspondence.........................................
Committee Oversight Findings..................................... 5
Statement of General Performance Goals and Objectives............ 5
Earmarks and Tax and Tariff Benefits............................. 5
Committee Cost Estimate.......................................... 5
Budget Authority and Congressional Budget Office Estimate........ 5
Federal Mandates Statement....................................... 8
Advisory Committee Statement..................................... 8
Applicability to Legislative Branch.............................. 8
Statement on Duplication of Federal Programs..................... 8
Section-by-Section Analysis of the Legislation................... 8
Changes in Existing Law Made by the Bill, as Reported............ 9
Minority Views................................................... 16
The amendment is as follows:
Strike all after the enacting clause and insert the
following:
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Vietnam Veterans Liver Fluke Cancer
Study Act''.
SEC. 2. STUDY ON THE PREVALENCE OF CHOLANGIOCARCINOMA IN VETERANS WHO
SERVED IN THE VIETNAM THEATER OF OPERATIONS DURING
THE VIETNAM ERA.
(a) Epidemiological Study.--Not later than 120 days after the date of
enactment of this Act, the Secretary of Veterans Affairs, in
consultation with the Director of the Centers for Disease Control and
Prevention of the Department of Health and Human Services, shall
commence an epidemiological study on the prevalence of
cholangiocarcinoma in covered veterans of the Vietnam era, using data
from the Veterans Affairs Central Cancer Registry and the National
Program of Cancer Registries. The study shall--
(1) identify the rate of incidence of cholangiocarcinoma in
covered veterans of the Vietnam era and in residents of the
United States, from the beginning of the Vietnam era to the
date of enactment of this Act; and
(2) for each of the groups specified in paragraph (1),
identify the percentage of individuals with cholangiocarcinoma
by various demographic characteristics, including by age,
gender, race, ethnicity, and the geographic location of the
patient at the time of diagnosis.
(b) Report to Congress.--Not later than one year after the completion
of the study under subsection (a), the Secretary shall submit to
Congress a report containing--
(1) the results of the study under subsection (a); and
(2) recommendations for administrative or legislative actions
required to address issues identified in the study under
subsection (a).
(c) Continued Tracking of Cholangiocarcinoma in Covered Veterans of
the Vietnam Era.--The Secretary shall track the prevalence of
cholangiocarcinoma in covered veterans of the Vietnam era using the
Veterans Affairs Central Cancer Registry, and provide such information
to Congress as required under subsection (d).
(d) Follow-Up Reports.--The Secretary shall periodically submit to
the Congress an updated report under subsection (b), as determined by
the Secretary.
(e) Definitions.--In this section:
(1) The term ``Secretary'' means the Secretary of Veterans
Affairs.
(2) The term ``Vietnam era'' has the meaning given such term
in section 101 of title 38, United States Code.
(3) The term ``covered veterans of the Vietnam era'' means
veterans who served in the Vietnam theater of operations during
the Vietnam era.
SEC. 3. MODIFICATION OF CERTAIN HOUSING LOAN FEES.
The loan fee table in section 3729(b)(2) of title 38, United States
Code, is amended by striking ``November 15, 2031'' each place it
appears and inserting ``November 29, 2031''.
Purpose and Summary
Page H.R. 4424, the ``Vietnam Veterans Liver Fluke Cancer
Study Act,'' was introduced by Representative Nick LaLota of
New York on June 30, 2023. H.R. 4424, as amended, would require
the U.S. Department of Veterans Affairs (VA), in consultation
with the Center for Disease Control, to begin an
epidemiological study on the prevalence of bile duct cancer in
Vietnam era veterans using data from the VA Central Cancer
Registry and the National Program of Cancer Registries. This
bill would also require the Secretary to periodically submit
updated reports to Congress.
Background and Need for Legislation
Section 1. Short Title
This Act may be cited as the ``Vietnam Veterans Liver Fluke
Cancer Study Act.''
Section 2. Study on the Prevalence of Cholangiocarcinoma in Veterans
Who Served in the Vietnam Theater of Operations During the
Vietnam Era
Liver fluke is a form of flatworm parasite that can infect
the bile ducks and liver of people through the consumption of
certain undercooked fish in Southeast Asia. The infection
caused by liver flukes can cause irritation and scarring that
can lead to bile duct cancer, also known as cholangiocarcinoma.
In 2018, the Northport VA Medical Center in New York conducted
a study on the prevalence of liver fluke in a group of 50
veterans from the Vietnam era. This study indicated that 24% of
Vietnam veterans who ate undercooked fish while deployed tested
positive or borderline positive for prior worm infection.
Initial reports and reviews on the study highlight the need for
more research on liver fluke and the development of standard
treatment procedures for veterans who have it.
Bile duct cancer is a relatively rare form of cancer in the
United States, with roughly 8,000 documented cases each year.
However, it is more common in Southeast Asia, where many
Vietnam era veterans were deployed during the November 1, 1955,
to May 7, 1975, timeframe. Bile duct cancer has other
documented causes in aging populations, thus the study required
in this bill would assist researchers and Congress in
determining if the cancer is a result of military deployment in
Southeast Asia or general aging.
This section would study whether bile duct cancer
disproportionately effects Vietnam War veterans, by studying
its prevalence in those veterans in comparison to the general
population. This information could be used by VA to determine
whether bile duct cancer among Vietnam War veterans, should be
considered presumptively service connected.
The mandated study in this section and subsequent report to
Congress aim to inform policy decisions, highlighting a
commitment to veteran welfare and the importance of evidence-
based decision making. The Committee believes that this section
could be a crucial step towards ensuring Vietnam veterans
receive care that they deserve. Particularly after facing poor
treatment in the form of anti-Vietnam War protests, and bias,
it is imperative that conditions which uniquely impact Vietnam
veterans, are studied with the same veracity as conditions
impacting more recent veteran populations.
Section 3. Modification of Certain Housing Loan Fees
Currently, veterans who take advantage of the VA Home Loan
Program pay a small fee that is included in their monthly
mortgage payment. This section would cover the costs of the
other section of this bill by extending the current rates for
VA home loan funding fees by two weeks to November 29, 2031.
Extending the funding fee increases a veteran's monthly cost by
about $5 on top of the monthly mortgage. Disabled veterans do
not pay the funding fee and would not be affected by this
extension of the home loan fees. The Committee believes this
short-term extension of current funding fee rates is a
reasonable way to cover the costs associated with the other
sections of this bill.
Hearings
On March 21, 2024, the Health Subcommittee held a
legislative hearing on H.R. 4424. The following witnesses
testified:
The Honorable Chairman Mike Bost, U.S. House of
Representatives, 12th Congressional District, Illinois;
The Honorable Chris Deluzio, U.S. House of
Representatives, 17th Congressional District,
Pennsylvania; The Honorable Jack Bergman, U.S. House of
Representatives, 1st Congressional District, Michigan;
The Honorable Greg Murphy, U.S. House of
Representatives, 3rd Congressional District, North
Carolina; The Honorable Derrick Van Orden, U.S. House
of Representatives, 3rd Congressional District,
Wisconsin; The Honorable Nick LaLota, U.S. House of
Representatives, 1st Congressional District, New York;
The Honorable Debbie Dingell, U.S. House of
Representatives, 6th Congressional District, Michigan;
The Honorable Lauren Underwood, U.S. House of
Representatives, 14th Congressional District, Illinois;
Dr. Ajit Pai, Executive Director, Office of
Rehabilitation and Prosthetics Services, Veterans
Health Administration; Dr. Michael Brenna, Executive
Director, Office of Construction and Facilities
Management, Veterans Affairs; Dr. Wendy Tenhula, Deputy
Chief Research and Development Officer, Office of
Research and Development, Veterans Health
Administration; Dr. David Perry, Chief Officer,
Workforce Management and Consulting, Veterans Health
Administration; Mr. Jon Retzer, Assistant National
Legislative Director, Disabled Americans Veterans; Mr.
Roscoe Butler, Senior Health Policy Advisor, Paralyzed
Veterans of America; Ms. Brittany Elliot, Veteran
(USMC), Advocate; Ms. Melissa Bryant, Chair, Board of
Directors, Minority Veterans of America.
The following individuals and organizations submitted
statements for the record:
Wounded Warrior Project, Treat Now, Superior
Ambulance.
Subcommittee Consideration
On April 16, 2024, the Health subcommittee met in an open
markup session, a quorum being present, and ordered H.R. 4424
to be reported favorably to the Full Committee by voice vote.
Committee Consideration
On May 1, 2024, the Full Committee met in open markup
session, a quorum being present, and ordered H.R. 4424, as
amended, be reported favorably to the House of Representatives
by voice vote.
An amendment in the nature of a substitute offered by
Chairman Bost of Illinois made a change to include an offset by
extending the home loan fee offset. The amendment in the nature
of substitute was approved by voice vote.
A motion by Ranking Member Takano of California to report
H.R. 4424, as amended, favorably to the House of
Representatives was agreed to by voice vote.
Committee Votes
In compliance with clause 3(b) of rule XIII of the Rules of
the House of Representatives, no recorded votes were taken with
ordering H.R. 4424, as amended, to the House.
Committee Oversight Findings
In compliance with clause 3(c)(1) of rule XIII and clause
(2)(b)(1) of rule X of the Rules of the House of
Representatives, the Committee's oversight findings and
recommendations are reflected in the descriptive portions of
this report.
Statement of General Performance Goals and Objectives
In accordance with clause 3(c)(4) of rule XIII of the Rules
of the House of Representatives, the Committee's performance
goals and objectives of H.R. 4424, as amended, are to study the
prevalence of cholangiocarcinoma in Vietnam era veterans and
report back to Congress.
Earmarks and Tax and Tariff Benefits
H.R. 4424, as amended, does not contain any Congressional
earmarks, limited tax benefits, or limited tariff benefits as
defined in clause 9 of rule XXI of the Rules of the House of
Representatives.
Committee Cost Estimate
[The Committee adopts as its own the cost estimate of H.R.
4424, as amended, prepared by the Director of the Congressional
Budget Office.]\1\
---------------------------------------------------------------------------
\1\Formal score forthcoming. CBO is hoping to get us the score soon
after this week's NDAA amendment process.
---------------------------------------------------------------------------
Budget Authority and Congressional Budget Office Cost Estimate
[Pursuant to clause (3)(c)(3) of rule XIII of the Rules of
the House of Representatives, the following is the cost
estimate for H.R. 4424, as amended, provided by the
Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974:]\2\
\2\Waiting on formal score.
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]
The bill would:
Require the Department of Veterans Affairs
(VA) to conduct a study on prevalence of
cholangiocarcinoma (cancer of the bile ducts that has
been linked to liver flukes)
Increase the fees that VA charges borrowers
for home loan guarantees
Estimated budgetary effects would mainly stem from:
Conducting a study on the prevalence of
cholangiocarcinoma
Increasing the fees charged by VA for home
loan guarantees
Bill summary: H.R. 4424 would require the Department of
Veterans Affairs (VA) to conduct a study on the prevalence of
cholangiocarcinoma (cancer of the bile ducts that has been
linked to liver flukes) among veterans who served during the
Vietnam era. The bill would also increase the fees that VA
charges borrowers for its home loan guarantees.
Estimated federal cost: The estimated budgetary effects of
H.R. 4424 are shown in Table 1. The costs of the legislation
fall within budget function 700 (veterans benefits and
services).
TABLE 1.--ESTIMATED BUDGETARY EFFECTS OF H.R. 4424
--------------------------------------------------------------------------------------------------------------------------------------------------------
By fiscal year, millions of dollars--
-----------------------------------------------------------------------------------------
2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2024-2029 2024-2034
--------------------------------------------------------------------------------------------------------------------------------------------------------
INCREASES IN SPENDING SUBJECT TO APPROPRIATION ESTIMATED AUTHORIZATION
Estimated Authorization....................................... * 1 * 1 * 1 * 1 * 1 * 3 5
Estimated Outlays............................................. * 1 * 1 * 1 * 1 * 1 * 3 5
INCREASES OR DECREASES (-) IN DIRECT SPENDING ESTIMATED BUDGET AUTHORITY
Estimated Budget Authority.................................... * * * * 1 * * * -22 1 * 1 -20
Estimated Outlays............................................. * * * * 1 * * * -22 1 * 1 -20
--------------------------------------------------------------------------------------------------------------------------------------------------------
* = between zero and $500,000.
Basis of estimate: For this estimate, CBO assumes that H.R.
4424 will be enacted in fiscal year 2024.
Provisions that affect spending subject to appropriation
and direct spending: Section 2 of the bill would require VA to
conduct a study on the prevalence of cholangiocarcinoma in
veterans from the Vietnam era and to continue to monitor
prevalence rates and periodically update that study. The
department is completing a study on the prevalence of
cholangiocarcinoma among Vietnam veterans. Based on information
from VA on the current staffing and support costs for that
study, CBO estimates the staffing and support costs required to
monitor prevalence rates and update the study would average
about $600,000 per year, and total about $7 million over the
2024-2034 period.
CBO expects that some of the costs of implementing the bill
would be paid from the Toxic Exposures Fund (TEF) established
by Public Law 117-168, the Honoring our PACT Act. The TEF is a
mandatory appropriation that VA uses to pay for health care,
disability claims processing, medical research, and IT
modernization that benefit veterans who were exposed to
environmental hazards.
Additional spending from the TEF would occur if legislation
increases the costs of similar activities that benefit veterans
with such exposure. CBO estimates that 18 percent of such
additional costs would be paid from the fund in 2025, growing
to 31 percent in 2034 as costs for those activities increase
over time. Those percentages are based on the amount of
formerly discretionary appropriations that CBO projects will be
provided through the mandatory appropriation as specified in
the Honoring our PACT Act. CBO estimates that over the 2024-
2034 period, implementing section 2 would increase spending
subject to appropriation by $5 million and direct spending by
$2 million.
Direct spending: The discussion above in ``Provisions that
affect spending subject to appropriation and direct spending''
describe provisions that would increase direct spending from
the Toxic Exposures Fund under H.R. 4424. The bill also would
increase fees paid for VA home loan guarantees, which would
decrease direct spending. In total, the bill would decrease
direct spending by $20 million over the 2024-2034 period.
H.R. 4424 would increase the fees that VA charges borrowers
for its loan guarantees. VA provides loan guarantees to lenders
that allow eligible borrowers to obtain better loan terms--such
as lower interest rates or smaller down payments--to purchase,
construct, improve, or refinance a home. VA typically pays
lenders up to 25 percent of the outstanding mortgage balance if
a borrower's home is foreclosed upon. Those payments, net of
fees paid by borrowers and recoveries by lenders, constitute
the subsidy cost for the loan guarantees.\1\ That subsidy cost
is reflected in the budget as direct spending.
---------------------------------------------------------------------------
\1\Under the Federal Credit Reform Act of 1990, the subsidy cost of
a loan guarantee is the net present value of estimated payments by the
government to cover defaults and delinquencies, interest subsidies, or
other expenses offset by any payments to the government, including
origination or other fees, penalties, and recoveries on defaulted
loans. Such subsidy costs are calculated by discounting those expected
cash flows using the rate on Treasury securities of comparable
maturity. The resulting estimated subsidy costs are recorded in the
budget when the loans are disbursed or modified. A positive subsidy
indicates that the loan results in net outlays from the Treasury; a
negative subsidy indicates that the loan results in net receipts to the
Treasury.
---------------------------------------------------------------------------
Under current law, the rates for most of the fees that
borrowers pay to VA for loans guaranteed after November 15,
2031, will drop from a weighted average of about 2.3 percent to
about 1.2 percent of the loan amount. The bill would extend the
higher rates through November 29, 2031, thereby reducing the
subsidy cost of loans guaranteed during that period. Using its
forecast of loan volume based on data provided by VA, CBO
estimates that extending the higher rates would decrease direct
spending by $22 million over the 2024-2034 period.
Pay-as-you-go considerations: The Statutory Pay-As-You-Go
Act of 2010 establishes budget-reporting and enforcement
procedures for legislation affecting direct spending or
revenues. The net changes in outlays that are subject to those
pay-as-you-go procedures are shown in Table 1.
Increase in long-term net direct spending and deficits: CBO
estimates that enacting H.R. 4424 would not increase net direct
spending by more than $2.5 billion in any of the four
consecutive 10-year periods beginning in 2035.
CBO estimates that enacting H.R. 4424 would not increase
on-budget deficits by more than $5 billion in any of the four
consecutive 10-year periods beginning in 2035.
Mandates: The bill contains no intergovernmental or
private-sector mandates as defined in the Unfunded Mandates
Reform Act.
Estimate prepared by: Federal costs: Matt Schmit (for
veterans health care); Paul B.A. Holland (for home loans).
Mandates: Brandon Lever.
Estimate reviewed by: David Newman, Chief, Defense,
International Affairs, and Veterans' Affairs Cost Estimates
Unit; Kathleen FitzGerald, Chief, Public and Private Mandates
Unit; Christina Hawley Anthony, Deputy Director of Budget
Analysis.
Estimate approved by: Phillip L. Swagel, Director,
Congressional Budget Office.
Federal Mandates Statement
[Section 423 of the Congressional Budget and Impoundment
Control Act (as amended by Section 101(a)(2) of the Unfunded
Mandate Reform Act, P.L. 104-4), is inapplicable to H.R. 4424,
as amended.]\3\
---------------------------------------------------------------------------
\3\Will confirm once receive formal score.
---------------------------------------------------------------------------
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act would be created by H.R.
4424, as amended.
Applicability to Legislative Branch
The Committee finds that H.R. 4424, as amended, does not
relate to the terms and conditions of employment or access to
public services or accommodation within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Statement on Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII of the Rules of the
House of Representatives, the Committee finds that no provision
of H.R. 4424, as amended, establishes or reauthorizes a program
of the Federal Government known to be duplicative of another
Federal program, a program that was included in any report from
the Government Accountability Office to Congress pursuant to
section 21 of Public Law 111-139, or a program related to a
program identified in the most recent Catalog of Federal
Domestic Assistance.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 would establish the short title as the ``Vietnam
Veterans Liver Fluke Cancer Study Act.''
Section 2. Study on the prevalence of cholangiocarcinoma in veterans
who served in the Vietnam theater of operations during the
Vietnam era
Section 2 would require the Secretary, in consultation with
the Director of the Centers for Disease Control, to conduct an
epidemiological study on the prevalence of cholangiocarcinoma
in covered veterans of the Vietnam era using data from the
Veterans Affairs Central Cancer Registry and the National
Program of Cancer Registries. This section would require the
Secretary to submit a report to Congress not later than one
year after the conclusion of the study, which would include the
result of the study and any recommendations for administrative
or legislative actions. This section would require the
Secretary to track the prevalence of cholangiocarcinoma in
covered Vietnam era veterans. The section would define
``Secretary,'' ``Vietnam era,'' and ``covered veterans of the
Vietnam era.''
Section 3. Modification of certain housing loan fees
Section three of the bill would provide funding for these
programs included in the bill by extending current rates for VA
home loan funding fees as established in section 3729 of title
38, U.S.C. from November 15, 2031, to November 29, 2031.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, existing law in which no change
is proposed is shown in roman):
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
TITLE 38, UNITED STATES CODE
* * * * * * *
PART III--READJUSTMENT AND RELATED BENEFITS
* * * * * * *
CHAPTER 37--HOUSING AND SMALL BUSINESS LOANS
* * * * * * *
SUBCHAPTER III--ADMINISTRATIVE PROVISIONS
* * * * * * *
Sec. 3729. Loan fee
(a) Requirement of Fee.--(1) Except as provided in subsection
(c), a fee shall be collected from each person obtaining a
housing loan guaranteed, insured, or made under this chapter,
and each person assuming a loan to which section 3714 of this
title applies. No such loan may be guaranteed, insured, made,
or assumed until the fee payable under this section has been
remitted to the Secretary.
(2) The fee may be included in the loan and paid from the
proceeds thereof.
(b) Determination of Fee.--(1) The amount of the fee shall be
determined from the loan fee table in paragraph (2). The fee is
expressed as a percentage of the total amount of the loan
guaranteed, insured, or made, or, in the case of a loan
assumption, the unpaid principal balance of the loan on the
date of the transfer of the property.
(2) The loan fee table referred to in paragraph (1) is as
follows:
----------------------------------------------------------------------------------------------------------------
Type of loan Active duty veteran Reservist Other obligor
----------------------------------------------------------------------------------------------------------------
(A)(i) Initial loan described in 2.15 2.40 NA
section 3710(a) to purchase or
construct a dwelling with 0-down, or
any other initial loan described in
section 3710(a) other than with 5-
down or 10-down (closed on or after
October 1, 2004, and before January
1, 2020).
(A)(ii) Initial loan described in 2.30 2.30 NA
section 3710(a) to purchase or
construct a dwelling with 0-down, or
any other initial loan described in
section 3710(a) other than with 5-
down or 10-down (closed on or after
January 1, 2020, and before April 7,
2023).
(A)(iii) Initial loan described in 2.15 2.15 NA
section 3710(a) to purchase or
construct a dwelling with 0-down, or
any other initial loan described in
section 3710(a) other than with 5-
down or 10-down (closed on or after
April 7, 2023, and before November
[15] 29, 2031).
(A)(iv) Initial loan described in 1.40 1.40 NA
section 3710(a) to purchase or
construct a dwelling with 0-down, or
any other initial loan described in
section 3710(a) other than with 5-
down or 10-down (closed on or after
November [15] 29, 2031).
(B)(i) Subsequent loan described in 3.30 3.30 NA
section 3710(a) to purchase or
construct a dwelling with 0-down, or
any other subsequent loan described
in section 3710(a) (closed on or
after October 1, 2004, and before
January 1, 2020).
(B)(ii) Subsequent loan described in 3.60 3.60 NA
section 3710(a) to purchase or
construct a dwelling with 0-down, or
any other subsequent loan described
in section 3710(a) (closed on or
after January 1, 2020, and before
April 7, 2023).
(B)(iii) Subsequent loan described in 3.30 3.30 NA
section 3710(a) to purchase or
construct a dwelling with 0-down, or
any other subsequent loan described
in section 3710(a) (closed on or
after April 7, 2023, and before
November [15] 29, 2031).
(B)(iv) Subsequent loan described in 1.25 1.25 NA
section 3710(a) to purchase or
construct a dwelling with 0-down, or
any other subsequent loan described
in section 3710(a) (closed on or
after November [15] 29, 2031).
(C)(i) Loan described in section 1.50 1.75 NA
3710(a) to purchase or construct a
dwelling with 5-down (closed before
January 1, 2020).
(C)(ii) Loan described in section 1.65 1.65 NA
3710(a) to purchase or construct a
dwelling with 5-down (closed on or
after January 1, 2020, and before
April 7, 2023).
(C)(iii) Loan described in section 1.50 1.50 NA
3710(a) to purchase or construct a
dwelling with 5-down (closed on or
after April 7, 2023, and before
November [15] 29, 2031).
(C)(iv) Loan described in section 0.75 0.75 NA
3710(a) to purchase or construct a
dwelling with 5-down (closed on or
after November [15] 29, 2031).
(D)(i) Loan described in section 1.25 1.50 NA
3710(a) to purchase or construct a
dwelling with 10-down (closed before
January 1, 2020).
(D)(ii) Loan described in section 1.40 1.40 NA
3710(a) to purchase or construct a
dwelling with 10-down (closed on or
after January 1, 2020, and before
April 7, 2023).
(D)(iii) Loan described in section 1.25 1.25 NA
3710(a) to purchase or construct a
dwelling with 10-down (closed on or
after April 7,
Minority Views
Liver fluke is a serious parasitic infection that is a
well-recognized risk factor for the development of bile duct
cancer. H.R. 4424, Vietnam Veterans Liver Fluke Cancer Study
Act, would require VA, in consultation with the Centers for
Disease Control and Prevention, to commence an epidemiological
study on the prevalence of bile duct cancer in veterans who
served in the Vietnam War versus their non-veteran U.S.
resident counterparts. VA would be required to submit a report
with the results of the study broken out by age, gender, race,
ethnicity and geographic location.
While Democratic Members are supportive of robust and
thorough research about the diseases veterans may have been
exposed to as part of their service, we believe VA raised valid
concerns in its written testimony at the Health Subcommittee's
legislative hearing on H.R. 4424. Specifically, VA believes
that the bill as written may be duplicative of past and ongoing
VA research efforts and may not advance understanding of the
link between liver fluke and cancer mortality rates, given the
study's required structure, which focuses on prevalence rather
than mortality. Furthermore, VA questioned whether the study
required by this legislation could be carried out successfully,
given a lack of reliable data.
In testimony provided at the Subcommittee on Health's
legislative hearing on March 21, 2024, the Department of
Veterans' Affairs stated:
Given VA's observations with existing studies, the
bill's requirements would not be as useful to the
agency as VA's current efforts at this time. Any
additional epidemiological study would face significant
hurdles in counting cases because of the lack of
available and comprehensive health care data (such as
cancer diagnoses and risk factors) on the entire
population of Vietnam-era Veterans over the years since
the war, whereas VA has conducted this mortality study
by compiling a roster of all Vietnam Veterans along
with a database of their death dates and causes.
Given VA's concerns, Democratic members have concerns about
using the results of any study that does not follow the
structure that VA outlined in its testimony to guide
conclusions about cancer causation links and presumptive
coverage decisions.
Mark Takano,
Ranking Member.
[all]